April 2026 marks a deliberate transition — stepping into a new chapter as advisor, board member and investor.
It is a transition grounded in twenty-five years in the off-patent medicines industry across Europe, Asia Pacific and MENA — the last seven at Zentiva, leading commercial operations across Western Europe as part of the executive team.
The non-compete over the past twelve months gave structure to what turned out to be a genuinely valuable pause. Time to reflect, to learn, to prepare — for what comes next.
Advise. Transform. Invest.
Looking forward to being back in the room.
